Is it possible to reduce the rate of vertical transmission and improve perinatal outcomes by inclusion of remdesivir in treatment regimen of pregnant women with COVID–19?

Table 2 Comparison of neonatal outcomes between the two study groups, in total and based on oxygen saturation

Variables	Categories	Total N	Remdesivir N = 54	Non–Remdesivir N = 135	Relative risk (95% confidence interval)	p–value
Preterm labor, N(%)	Total	169	18(36.7%)	45(37.5%)	0.98(0.63–1.51)	0.92^*
	SPO₂ ≥ 94%	130	13(36.1%)	33(35.1%)	1.02(0.61–1.72)	0.91^*
	SPO₂ < 94%	39	5(38.5%)	12(46.2%)	0.83(0.37–1.86)	0.64^*
Postdate pregnancy, N(%)	Total	169	1(2%)	7(5.8%)	0.35(0.44–2.76)	0.26^†
	SPO₂ ≥ 94%	130	0(0%)	6(5.6%)	–^‡	0.13^†
	SPO₂ < 94%	39	1(7.7%)	1(3.8%)	2(0.13–29.4)	0.56^†
NICU admission, N(%)	Total	170	7((13.7%)	30(25.2%)	0.54(0.2–1.15)	0.09^*
	SPO₂ ≥ 94%	134	3(8.1%)	24(24.7%)	0.32(0.105–1.02)	0.03^*
	SPO₂ < 94%	36	4(28.6%)	6(27.3%)	1.04(0.35–3.06)	0.61^†
Neonatal death, N(%)	Total	177	1(1.9%)	9(7.2%)	0.26(0.35–2.05)	0.15^†

Abbreviations: SPO₂ Saturation of peripheral oxygen, NICU Newborn intensive care unit, PCR Polymerase chain reaction test
^*The results of Chi square test, ^†The result of Fisher’s exact test, ^‡One cell of 2 × 2 table has observed count 0; therefore, RR is not computable

ISSN: 1471-2393